Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer

NCT ID: NCT02527824

Last Updated: 2017-08-23

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-31
• Study Completion Date: 2017-09-30

Brief Summary

This study will conduct a phase II study of triple combination with oxaliplatin, irinotecan, and S-1 as the first-line chemotherapy in patients with advanced biliary tract cancer.

Detailed Description

It is widely accepted that the efficacy of chemotherapy for patients with inoperable, advanced, and metastatic biliary tract cancer is better than that compared to best supportive care. In general, gemcitabine based combination chemotherapies are considered as the first line treatment for patients with advanced biliary tract cancer, but these have some limitations of inconvenience of administration and unsatisfactory efficacy.

S-1 monotherapy and combination with oxaliplatin have shown the objective response rate of 21-35% and 24.5%, respectively, and irinotecan combined with oxaliplatin has shown the response rate of 18-20.5% in patients with advanced metastatic biliary tract cancer. So the investigators had conducted the phase I study of three drugs (oxaliplatin, irinotecan, and S-1) with modification of dosage and schedule and will conduct a phase II study with recommended dose of triple chemotherapy from this phase I study.

Conditions

Biliary Tract Neoplasm

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Oxaliplatin, Irinotecan, S-1(OIS)

intervention with triple combination chemotherapy with oxaliplatin, irinotecan, and S-1 Treatment will be delivered as a 2-week cycle.

1. Oxaliplatin 65 mg/m2 iv on day 1

2. Irinotecan 135 mg/m2 iv on day 1

3. S-1 80 mg/m2/day on day 1-7

Group Type: EXPERIMENTAL

Oxaliplatin, Irinotecan, S-1

Intervention Type: DRUG

Treatment will be delivered every 2 weeks

1. Oxaliplatin 65 mg/m2 iv on day 1

2. Irinotecan 135 mg/m2 iv on day 1

3. S-1 80 mg/m2/day on day1-7

Interventions

Oxaliplatin, Irinotecan, S-1

Treatment will be delivered every 2 weeks

1. Oxaliplatin 65 mg/m2 iv on day 1

2. Irinotecan 135 mg/m2 iv on day 1

3. S-1 80 mg/m2/day on day1-7

Intervention Type: DRUG

Other Intervention Names

Liplatin, Inotecan, TS-1(tegafur, gimeracil, oteracil)

Eligibility Criteria

Inclusion Criteria

• Pathologically confirmed advanced, recurrent or metastatic adenocarcinoma of biliary tract system (stage IV by primary tumor, regional nodes, metastasis(TNM) staging system)
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• More than 3 months expected life span
• Measurable lesion by RECIST criteria version 1.1
• Palliative chemotherapy naive
• Adequate organ functions
• Participants must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital

Exclusion Criteria

• Any prior 2 years or concurrent malignancy other than non-melanoma skin cancer, in situ cancer of uterine cervix, or papillary or follicular thyroid cancer.
• Participants who had received radiation therapy for target lesions 4 weeks before study enrollment
• Participants who had received major surgery 4 weeks before study enrollment
• Participants with active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus, myocardial infarction during the preceding 12 months, pregnancy, or breast feeding
• Participants with central nervous system(CNS) metastases
• Participants with peripheral sensory neuropathies with impaired functional activities
• Participants with gastrointestinal obstruction or bleeding inducing mal-absorption of oral chemotherapeutic agents.

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jeil Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Hallym University Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dae Young Zang, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Hallym University Medical Center

Locations

Hallym university medical center

Anyang, Gyunggi, South Korea

Countries

South Korea

Other Identifiers

HMC-HO-GI-1501

Identifier Type: -

Identifier Source: org_study_id